Healthcare PharmaceuticalsVyvanse
Owned by Takeda Pharmaceutical Company
Takeda's once-daily amphetamine prodrug (lisdexamfetamine dimesylate) for ADHD and binge eating disorder, originally developed by New River Pharmaceuticals and acquired by Shire in 2007 (the year of FDA approval), with Takeda inheriting the brand through its $62 billion acquisition of Shire in 2019, before generic lisdexamfetamine was approved in 2023.
adhdlisdexamfetaminebinge-eating-disorder